17 Recruiting Carcinoma, Non-Small-Cell Lung Phase 3 Clinical Trials
Active phase 3 studies for carcinoma, non-small-cell lung enrolling across the USA. Verify eligibility and contact site coordinators.
All Carcinoma, Non-Small-Cell Lung studiesPhase 3 Studies for Carcinoma, Non-Small-Cell Lung
🔵 Active, Not Recruiting Phase3
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
📍 Local Institution - 0221 — Des Moines, Iowa
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
📍 City of Hope 2 — Duarte, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
📍 UCLA Hematology/Oncology - Santa Monica — Los Angeles, California
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
📍 Local Institution - 0104 — Tampa, Florida
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
📍 Florida Cancer Specialists — Altamonte Springs, Florida
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
📍 Research Site — Beijing,
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
📍 Research Site — Tuscaloosa, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
📍 Rush University Medical Center — Chicago, Illinois
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
📍 Infirmary Cancer Care ( Site 0418) — Mobile, Alabama
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
📍 Alaska Oncology and Hematology, LLC — Anchorage, Alaska
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
📍 Oncocentro Serviços Médicos e Hospitalares Ltda — Fortaleza, Ceará
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
📍 Arizona Oncology Associates, PC - HAL — Goodyear, Arizona
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase3
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
📍 Southern Cancer Center, PC — Mobile, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
📍 Banner MD Anderson Cancer Center ( Site 0181) — Gilbert, Arizona
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
📍 Clearview Cancer Institute — Huntsville, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase3
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
📍 Clearview Cancer Institute — Huntsville, Alabama
View Study & Checklist ➔ 🟢 Recruiting Phase3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
📍 Local Institution - 0347 — Birmingham, Alabama
View Study & Checklist ➔